Endothelial Dysfunction and Platelet Hyperactivation in Diabetic
                    Complications Induced by Glycemic Variability

Ye Huang; Long Yue; Jiahuang Qiu; Ming Gao; Sijin Liu; Jingshang Wang

doi:10.1055/a-1880-0978

Hormone and Metabolic Research, Table of Contents

CC BY-NC-ND 4.0 · Horm Metab Res 2022; 54(07): 419-428
DOI: 10.1055/a-1880-0978

Review

Endothelial Dysfunction and Platelet Hyperactivation in Diabetic Complications Induced by Glycemic Variability

Ye Huang

¹Emergency Department, China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China

,

Long Yue

¹Emergency Department, China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China

,

Jiahuang Qiu

²Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, China

,

Ming Gao

²Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, China

,

Sijin Liu

²Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing, China

,

Jingshang Wang

³Department of Traditional Chinese Medicine, Capital Medical University Beijing Obstetrics and Gynecology Hospital, Beijing, China

› Author Affiliations

Abstract

The development and progression of the complications of chronic diabetes mellitus are attributed not only to increased blood glucose levels but also to glycemic variability. Therefore, a deeper understanding of the role of glycemic variability in the development of diabetic complications may provide more insight into targeted clinical treatment strategies in the future. Previously, the mechanisms implicated in glycemic variability-induced diabetic complications have been comprehensively discussed. However, endothelial dysfunction and platelet hyperactivation, which are two newly recognized critical pathogenic factors, have not been fully elucidated yet. In this review, we first evaluate the assessment of glycemic variability and then summarise the roles of endothelial dysfunction and platelet hyperactivation in glycemic variability-induced complications of diabetes, highlighting the molecular mechanisms involved and their interconnections.

Key words

diabetes mellitus - glycaemic variability - endothelial dysfunction - platelet hyperactivation

Full Text

References

References
1 Tuomilehto J, Lindstrom J, Eriksson JG. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
2 Dal Canto E, Ceriello A, Rydén L. et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019; 26: 25-32
3 Zaccardi F, Pitocco D, Ghirlanda G. Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab Res Rev 2009; 25: 199-207
4 Muggeo M, Verlato G, Bonora E. et al. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia 1995; 38: 672-679
5 Muggeo M, Verlato G, Bonora E. et al. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997; 96: 1750-1754
6 Zhou JJ, Koska J, Bahn G. et al. Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes Trial. Diab Vasc Dis Res 2019; 16: 178-185
7 Nordwall M, Arnqvist HJ, Bojestig M. et al. Good glycemic control remains crucial in prevention of late diabetic complications-the Linkoeping Diabetes Complications Study. Pediatr Diabetes 2009; 10: 168-176
8 Sakamoto M. Type 2 Diabetes and glycemic variability: various parameters in clinical practice. J Clin Med Res 2018; 10: 737-742
9 Monnier L, Colette C, Boegner C. et al. Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom?. Diabetes Metab 2007; 33: 247-252
10 Lachin JM, Bebu I, Bergenstal RM. et al. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial. Diabetes Care 2017; 40: 777-783
11 Zhou JJ, Schwenke DC, Bahn G. et al. Glycemic variation and cardiovascular risk in the Veterans Affairs Diabetes Trial. Diabetes Care 2018; 41: 2187-2194
12 Ceriello A, Kilpatrick ES. Glycemic variability: both sides of the story. Diabetes Care 2013; 36: S272-S275
13 Picard F, Adjedj J, Varenne O. Diabetes mellitus, a prothrombotic disease. Ann Cardiol Angeiol 2017; 66: 385-392
14 Tylee TS, Trence DL. Glycemic variability: looking beyond the A1C. Diabetes. Spectrum 2012; 25: 149-153
15 Pandit K. Continuous glucose concentration monitoring. Indian J Endocrinol Metab 2012; 16: S263-S266
16 Monnier L, Colette C. Glycemic variability: should we and can we prevent it?. Diabetes Care 2008; 31: S150-S154
17 Stratton IM, Adler AI, Neil HA. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412
18 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003; 26: 881-885
19 Cameron FJ, Donath SM, Baghurst PA. Measuring glycaemic variation. Curr Diabetes Rev 2010; 6: 17-26
20 Service FJ, Molnar GD, Rosevear JW. et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19: 644-655
21 Kohnert KD, Heinke P, Vogt L. et al. Utility of different glycemic control metrics for optimizing management of diabetes. World J Diabetes 2015; 6: 17-29
22 Hill HR, Hindmarsh PC, Stevens RJ. et al. A method for assessing quality of control from glucose profiles. Diabet Med 2007; 24: 753-758
23 Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Therap 2009; 11: S55-S67
24 Shima K, Tanaka R, Morishita S. et al. Studies on the etiology of “brittle diabetes”. Relationship between diabetic instability and insulinogenic reserve. Diabetes 1977; 26: 717-725
25 Guillermo EU, Boris PK. Glycemic variability: how to measure and its clinical implication for type 2 diabetes. Am J Med Sci 2018; 356: 518-527
26 Bergenstal RM. Glycemic variability and diabetes complications: does it matter? simply put, there are better glycemic markers!. Diabetes Care 2015; 38: 1615-1621
27 Muggeo M, Zoppini G, Bonora E. et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: The Verona Diabetes Study. Diabetes Care 2000; 23: 45-50
28 Bragd J, Adamson U, Backlund LB. et al. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?. Diabetes Metab 2008; 34: 612-616
29 Kovatchev BP, Cox DJ, Gonder-Frederick LA. et al. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998; 21: 1870-1875
30 Kovatchev BP. Metrics for glycaemic control–from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol 2017; 13: 425-436
31 Alemzadeh R, Loppnow C, Parton E. et al. Glucose sensor evaluation of glycemic instability in pediatric type 1 diabetes mellitus. Diabetes Technol Ther 2003; 5: 167-173
32 Kovatchev BP, Otto E, Cox D. et al. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006; 29: 2433-2438
33 Service FJ, Nelson RL. Characteristics of glycemic stability. Diabetes Care 1980; 3: 58-62
34 Ryan EA, Shandro T, Green K. et al. Assessment of the severity of hypoglycemia and glycemic lambility in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004; 53: 955-962
35 Nusca A, Pantano AL, Melfi R. et al. Glycemic variability assessed by continuous glucose monitoring and short-term outcome in diabetic patients undergoing percutaneous coronary intervention: an observational pilot study. J Diabetes Res 2015; 250201
36 Metzger M, Leibovitz G, Wainstein J. et al. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 2002; 25: 1185-1191
37 Danne T, Nimri R, Battelino T. et al. International consensus on use of continuous glucose monitoring. Diabetes Care 2017; 40: 1631-1640
38 Battelino T, Danne T, Bergenstal RM. et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019; 42: 1593-1603
39 Kilpatrick ES. Arguments for and against the role of glucose variability in the development of diabetes complications. J. Diabetes Sci Technol 2009; 3: 649-655
40 Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010; 12: 288-298
41 Caprnda M, Mesarosova D, Ortega PF. et al. Glycemic variability and vascular complications in patients with type 2 diabetes mellitus. Folia Medica 2017; 59: 270-278
42 Paneni F, Costantino S, Cosentino F. Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. Cardiovasc Diagn Ther 2014; 4: 324-332
43 Jung HS. Clinical implications of glucose variability: chronic complications of diabetes. Endorinol Metab 2015; 30: 167-174
44 Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab 2013; 15: 3-8
45 Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26: 77-82
46 Ceriello A, Kilpatrick ES. Glycemic variability: both sides of the story. Diabetes Care 2013; 36: S272-S275
47 Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010; 12: 288-298
48 Cardoso CRL, Leite NC, Moram CBM. et al. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol 2018; 17: 33
49 Lachin JM, Genuth S, Nathan DM. et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008; 57: 995-1001
50 Smith-Palmer J, Brandle M, Trevisan R. et al. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract 2014; 105: 273-284
51 DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983
52 Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376: 124-136
53 Hsu CR, Chen TY, Sheu WHH. Glycemic variability and diabetes retinopathy: a missing link. J Diabetes Complicat 2015; 29: 302-306
54 Schreur V, van Asten F, Ng H. et al. Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus. Acta Ophthalmol 2018; 96: 459-464
55 Yang YF, Li TC, Li CI. et al. Visit-to-visit glucose variability predicts the development of end-stage renal disease in type 2 diabetes: 10-year follow-up of Taiwan diabetes study. Medicine 2015; 94: e1804
56 Kwai NCG, Arnold R, Poynten AM. et al. Association between glycemic variability and peripheral nerve dysfunction in type 1 diabetes. Muscle Nerve 2016; 54: 967-969
57 Nyiraty S, Pesei F, Orosz A. et al. Cardiovascular autonomic neuropathy and glucose variability in patients with Type 1 diabetes: is there an association?. Front Endocrinol 2018; 9: 174
58 Matsutani D, Sakamoto M, Iuchi H. et al. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. Cardiovasc Diabetol 2018; 17: 36
59 Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol 2019; 7: 221-230
60 Yang CP, Li Cl, Lin WY. et al. Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM. Neurology 2017; 88: 944-951
61 Anand SS, Islam S, Rosengren A. et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008; 29: 932-940
62 Zhang X, Xu X, Jiao X. et al. The effects of glucose fluctuation on the severity of coronary artery disease in type 2 diabetes mellitus. J. Diabetes Res 2013; 2013: 576916
63 Beliaeva N, Strongin L, Baranov E. The impact of glycemic variability on local contractility of the left ventricular in acute period of myocardial infarction. Cardiology 2013; 126: 93
64 Gerbaud E, Darier R, Montaudon M. et al. Glycemic variability is a powerful independent predictive factor of midterm major adverse cardiac events in patients with diabetes with acute coronary syndrome. Diabetes Care 2019; 42: 674-681
65 Takahashi H, Iwahashi N, Kirigaya J. et al. Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome. Cardiovasc Diabetol 2018; 17: 116
66 Francesco M, Lorenzo C, Domenico C. Glycaemic control and vascular complications in diabetes mellitus type 2. Adv Exp Med Biol 2021; 1307: 129-152
67 Huang J, Zhang X, Li J. et al. Impact of glucose fluctuation on acute cerebral infarction in type 2 diabetes. Can J Neurol Sci 2014; 41: 486-492
68 Wattankit K, Folsom AR, Selvin E. et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2005; 180: 389-397
69 Yang CP, Lin CC, Li CL. et al. Fasting plasma glucose variability and HbA1c are associated with peripheral artery disease risk in type 2 diabetes. Cardiovasc Diabetol 2020; 19: 4
70 Tabit CE, Chung WB, Hamburg NM. et al. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010; 11: 61-74
71 Carrizzo A, Lzzo C, Oliveti M. et al. The main determinants of diabetes mellitus vascular complications: endothelial dysfunction and platelet hyperaggregation. Int J Mol Sci 2018; 19: 2968
72 Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes 2017; 9: 434-449
73 Jung HS. Clinical implications of glucose variability: chronic complications of diabetes. Endocrinol Metab 2015; 30: 167-174
74 Cerielo A, Taboga C, Tonutti L. et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation 2002; 106: 1211-1218
75 Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol 2019; 11: 45-63
76 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625
77 Monnier L, Mas E, Ginet C. et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687
78 Wang J-S, Huang Y, Zhang S. et al. A protective role of paeoniflorin in fluctuant hyperglycemia induced vascular endothelial injuries through anti-oxidative and anti-inflammatory effects and reduction of PKCβ1. Oxid Med Cell Longev 2019; 5647219
79 Risso A, Mercuri F, Quagliaro L. et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001; 281: E924-E930
80 Quagliaro L, Piconi L, Assaloni R. et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003; 52: 2795-2804
81 Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006; 147: S193-S201
82 Forte M, Conti V, Damato A. et al. Targeting nitric oxide with natural derived compounds as a therapeutic strategy in vascular diseases. Oxid Med Cell Longev 2016; 7364138
83 Tousoulis D, Kampoli AM, Stefanadis C. Diabetes mellitus and vascular endothelial dysfunction: current perspectives. Curr Vasc Pharmacol 2011; 10: 19-32
84 Puca AA, Carrizzo A, Ferrario A. et al. Endothelial nitric oxide synthase, vascular integrity and human exceptional longevity. Immun Ageing 2012; 9: 26
85 Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Investig 1997; 100: 2153-2157
86 Halim M, Halim A. The effects of inflammation, aging and oxidative stress on the pathogenesis of diabetes mellitus (type 2 diabetes). Diabetes Metab Syndr 2019; 13: 1165-1172
87 Otsuka A, Azuma K, Iesaki T. et al. Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia 2005; 48: 2667-2674
88 Watada H, Azuma K, Kawamori R. Glucose fluctuation on the progression of diabetic macroangiopathy-new findings from monocyte adhesion to endothelial cells. Diabetes Res Clin Pract 2007; 77: S58-S61
89 Mita T, Otsuka A, Azuma K. et al. Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2008; 358: 679-685
90 Piconi L, Quagliaro L, Da Ros R. et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004; 2: 1453-1459
91 Quagliaro L, Piconi L, Assaloni R. et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005; 183: 259-267
92 Liu T, Gong J, Chen Y. et al. Periodic vs constant high glucose in inducing pro-inflammatory cytokine expression in human coronary artery endothelial cells. Inflamm Res 2013; 62: 697-701
93 Esposito K, Nappo F, Marfella R. et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072
94 Shanmugam N, Reddy MA, Guha M. et al. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003; 52: 1256-1264
95 Wu N, Shen HT, Liu HN. et al. Acute blood glucose fluctuation enhances rat aorta endothelial cell apoptosis, oxidative stress and pro-inflammatory cytokine expression in vivo. Cardiovasc Diabetol 2016; 15: 109
96 Buch A, Kaur S, Nair R. et al. Platelet volume indices as predictive biomarkers for diabetic complications in type 2 diabetic patients. J Lab Physicians 2017; 9: 84-88
97 Gaiz A, Mosawy S, Colson N. et al. Thrombotic and cardiovascular risks in type two diabetes; Role of platelet hyperactivity. Biomed Pharmacother 2017; 94: 679-686
98 Rollini F, Franchi F, Muñiz-Lozano A. et al. Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl Res 2013; 6: 329-345
99 Ang L, Palakodeti V, Khalid A. et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2009; 52: 1052-1059
100 Kodiatte TA, Manikyam UK, Rao SB. et al. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians 2012; 4: 5-9
101 Walinjkar RS, Khadse S, Kumar S. et al. Platelet indices as a predictor of microvascular complications in type 2 diabetes. Indian J Endocrinol Metab 2019; 23: 206-210
102 Davì G, Catalano I, Averna M. et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-1774
103 Gresele P, Guglielmini G, De Angelis M. et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-1020
104 Davi G, Alessandrini P, Mezzetti A. et al. In vivo formation of 8-Iso-Prostaglandin F-2 alpha is increased in hypercholesterolemia. An aspirin-insensitive amplification mechanism of platelet activation. Thromb Res 1998; 91: S131
105 Basili S, Pacini G, Guagnano MT. et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2008; 48: 2531-2538
106 Huang Y, Wang J-S, Yang L. et al. Paeoniflorin ameliorates glycemic variability-induced oxidative stress and platelet activation in HUVECs and DM rats. RSC Adv 2020; 10: 42605-42612
107 Linden MD, Tran H, Woods R. et al. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 2012; 38: 200-212
108 Tang WH, Stitham J, Gleim S. et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest 2011; 121: 4462-4476
109 Vinik AI, Erbas T, Park TS. et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-1485
110 Tschoepe D. The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin Thromb Hemost 1995; 21: 152-160
111 Assert R, Scherk G, Bumbure A. et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001; 44: 188-195
112 Millican SA, Schultz D, Bagga M. et al. Glucose-modified low density lipoprotein enhances human monocyte chemotaxis. Free Rad Res 1998; 28: 533-542
113 Ferretti G, Rabini RA, Bacchetti T. et al. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 2002; 87: 2180-2184
114 Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 2007; 7: 223-227
115 Kessler L, Wiesel ML, Attali P. et al. Von Willebrand factor in diabetic angiopathy. Diabetes Metab 1998; 24: 327-336
116 Gresele P, Guglielmini G, De Angelis M. et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-1020
117 Patti G, Cavallari I, Andreotti F. et al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 2019; 16: 113-130
118 Nusca A, Tuccinardi D, Pieralice S. et al. Platelet effects of anti-diabetic therapies: new perspectives in the management of patients with diabetes and cardiovascular disease. Front Pharmacol 2021; 12: 670155
119 King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999; 48: 643-648
120 Lehert P, Bets D, Donker AJ. et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169: 616-625
121 Schaeffer G, Wascher TC, Kostner GM. et al. Alterations in platelet Ca²⁺signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia 1999; 42: 167-176
122 Spinetti G, Kraenkel N, Emanueli C. et al. Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovasc Res 2008; 78: 265-273
123 Frankel DS, Meigs JB, Massaro JM. et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: The framingham offspring study. J Vasc Surg 2009; 50: 235
124 van Schie MC, de Maat MP, Isaacs A. et al. Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood 2011; 117: 1393-1399
125 Xiang Y, Cheng J, Wang D. et al. Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood 2015; 125: 3377-3387
126 Etheresia P. Platelets as potent signaling entities in type 2 diabetes mellitus. Trends Endocrinol Metab 2019; 30: 532-545
127 Quehenberger P, Bierhaus A, Fasching P. et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 2000; 49: 1561-1570
128 Xu B, Chibber R, Ruggiero D. et al. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17: 1289-1291
129 Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-438
130 Hangaishi M, Taguchi J, Miyata T. et al. Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem. Biophys Res Commun 1998; 248: 285-292
131 Gawlowski T, Stratmann B, Ruetter R. et al. Advanced glycation end products strongly activate platelets. Eur J Nutr 2009; 48: 475-481
132 Zhu W, Li W, Silverstein RL. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36. Blood 2012; 119: 6136-6144
133 Zhang X, Zhang J, Li J. et al. Relationship between 24h venous blood glucose variation and mortality among patients with acute respiratory failure. Sci Rep 2021; 11: 7747